Whitehawk Data Bolsters MUC16 as Durable Target for Ovarian Cancer ADCs — Whitehawk Therapeutics, Inc.

Event summary

Whitehawk presented real-world data at IGCS 2026 showing MUC16 expression remains stable across multiple ovarian cancer treatments.
High MUC16 expression correlated with poorer overall survival in high-grade serous ovarian carcinoma (HGSOC).
HWK-016, Whitehawk's MUC16-directed ADC, is in Phase 1 trials for advanced ovarian and endometrial cancers.
Data suggests MUC16 is a more durable target than FRα, TROP2, and NaPi2b in ovarian cancer.

The big picture

Whitehawk's findings reinforce MUC16 as a promising ADC target in ovarian cancer, addressing a critical need for durable therapies in a disease with high recurrence rates. The stability of MUC16 expression across treatments suggests potential for both early and late-line applications, positioning HWK-016 as a key asset in Whitehawk's ADC pipeline. The data also highlights the growing role of real-world evidence in validating oncology targets, a trend accelerating as precision medicine advances.

What we're watching

Clinical Validation: Whether Phase 1 data for HWK-016 will confirm MUC16's durability as a therapeutic target in ovarian cancer.
Competitive Positioning: How Whitehawk's MUC16-directed ADC will differentiate against existing treatments like mirvetuximab soravtansine.
Development Strategy: The pace at which Whitehawk advances HWK-016 into combination therapies and relapsed settings.